CN106822152A - A kind of pharmaceutical composition and its application - Google Patents
A kind of pharmaceutical composition and its application Download PDFInfo
- Publication number
- CN106822152A CN106822152A CN201611238398.8A CN201611238398A CN106822152A CN 106822152 A CN106822152 A CN 106822152A CN 201611238398 A CN201611238398 A CN 201611238398A CN 106822152 A CN106822152 A CN 106822152A
- Authority
- CN
- China
- Prior art keywords
- parts
- pharmaceutical composition
- acid
- quercetin
- active component
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a kind of pharmaceutical composition, its active component includes Quercetin, RV, tanshin polyphenolic acid B and ganoderic acid A.In the active component, Quercetin:RV:Tanshin polyphenolic acid B:The weight ratio of ganoderic acid A is 5 30:10‑40:40‑200:1‑6.Described pharmaceutical composition can also include rheum emodin.Invention also provides described pharmaceutical composition formulation can be tablet, pill, powder, granule, mixture, syrup, capsule or pill, and its prepare treatment oxyhepatitis and chronic hepatitis medicine in application.The mutual compatibility of each composition of active component in the present invention, plays synergistic function, can from Mutiple Targets, multi-angle, treat hepatitis disease at many levels, toxic and side effect and delay drug-fast advantage with mitigating.
Description
Technical field
The present invention relates to technical field of traditional Chinese medicines, and in particular to a kind of pharmaceutical composition and its application.
Background technology
Hepatitis is the general designation of inflammation.Typically refer to by various paathogenic factors -- such as virus, bacterium, parasite, chemistry
Poisonous substance, medicine, alcohol, role of autoimmune factors etc. are destroyed liver cell, and the function of liver suffers damage, and cause body one
Serial malaise symptoms, and liver function index exception.According to course of disease length, hepatitis can be divided into oxyhepatitis, chronic hepatitis
Deng.In global range, the hepatitis burden of China is most heavy：Global 2.4 hundred million Chronic Patients with HBV Infection have 1/3rd in China,
Global 1.3 to 1.5 hundred million hepatitis c virus infection persons about 7% are also in China.The World Health Organization is to China to be represented doctor Shi Hede and claims：
" China there are about 100,000,000 people --- namely just having 1 people in every 13 people --- be chronic hepatitis B virus and hepatitis c virus infection person, its
Middle most people do not know that oneself carries virus.Hepatitis, really into a kind of ' noiseless epidemic situation '.If these people are not controlled
Treat, wherein it is the fatal diseases such as cancer that the Infection Status of 1/3rd people can deteriorate.
The novel compound new drug development cycle is long, input is big, technical difficulty is high, is difficult to see benefit in 10 years.Therefore,
Exploitation can treat the composition of hepatitis, also be increasingly becoming the emphasis direction of new hepatitis medicine research and development.
China's application (publication number：CN104435239A a kind of Chinese medicine composition for preventing and treating hepatitis) is disclosed, it includes：Ox
Energetically, black tiger, hypericum japonicum, Common Leafflower Herb, ternateleaf rabdosia herb, oldenlandia diffusa, Radix Glycyrrhizae.However, it has, process route is rougher, have
Effect composition is indefinite, quality standard is low, causes the shortcomings of product differences between batches are big, drug quality stability is poor.
Nucleoside analog is combined for hepatitis treatment individually or with other antiretroviral drugs, has there is lactate
The hepatomegaly of acid poisoning and severe with steatosis, including death report.When chronic hepatitis B patients stop anti-second
After liver treatment, it has been found that have the report that severe acute hepatitis is broken out.Chemical drug treatment hepatitis produces the situation of drug resistance very common.
In view of this, it is special to propose the present invention.
The content of the invention
The first object of the present invention is to provide a kind of pharmaceutical composition, can be from Mutiple Targets, multi-angle, multi-level treatment
Hepatitis disease, to mitigate toxic and side effect and delay the resistance to the action of a drug.
To achieve the above object, the present invention is adopted the following technical scheme that：
A kind of pharmaceutical composition, its active component includes Quercetin, RV, tanshin polyphenolic acid B and ganoderic acid A.
The present invention is combined on the basis of a large amount of pharmacodynamic experiments by the different compatibilities to various related drugs, is obtained
Scientific composition of the invention.Scientific composition of the invention combines the advantage of Chinese medicine and Western medicine, in the mechanism of action from Mutiple Targets,
Multi-angle, synergistic function has been given play at many levels, solved the limitation of single medicine effect.Because each Ingredient Amount is far low
In dosage is used alone, so can also delay drug-fast generation while toxic and side effect is mitigated, avoid to the full extent
The non-selectivity toxic and side effect of general chemotherapeutics and the generation of drug resistance.
The present invention is using Quercetin, RV, tanshin polyphenolic acid B and ganoderic acid A compatibilities as active component, it has unexpectedly been found that
Prescription effect uses the summation of the therapeutic effect for reaching respectively more than medicine in prescription.
Wherein, Quercetin (Quercetin)：Also known as quercetin, Quercetin, MeletinSophoretin.Molecular formula is
C15H10O7, molecular weight 302.23, yellow crystal (C15Hl0072H20), fusing point (mp)：313-314 DEG C (decomposition), it is anhydrous
Thing mp：316℃.It is dissolved in hot ethanol, cold ethanol, methyl alcohol, ethyl acetate, pyridine etc.；Insoluble in petroleum ether, benzene, ether and chloroform,
It is practically insoluble in water.With preferable eliminating the phlegm, antitussive action, and there can be certain antiasthmatic effect as medicine.In addition with drop
Low blood pressure, enhancing capillary resistance, reduction capillary fragility, reducing blood lipid, coronary artery dilator, increase CF
Deng effect.For treating chronic bronchitis, also there is auxiliary therapeutic action to coronary heart disease and hyperpietic.Quercitrin have anti-many
The effect of kind of virus, mechanism of action is that it can suppress lysosome H-ATP enzymes, phosphate A and has a decrustation, influence virus transfer
The phosphorylation of gene, suppresses virus protein and RNA synthesis.
White reed lamb's-quarters alcohol, also known as resvertrol, Resveratrol, (E) -5-2- (4- hydroxyphenyls)-vinyl -1,3- benzene
Diphenol, chemical formula (molecular formula)：C14H12O3, is a kind of white powder, is that one kind has important physiologically active polyphenols,
It is main composition in various plants body, can be widely applied to food, health products, medicine and other fields.White reed lamb's-quarters alcohol is by suppression
Hepaitis B virus DNA replication dna processed, the Apoptosis of inductive infection Hepaitis B virus and play antiviral activity.
Tanshin polyphenolic acid B, alias lithospermic acid B, danshinolic acid second are condensed and are formed by the danshensu of 3 molecules and the caffeic acid of 1 molecule,
Chemical formula is C36H30O16, can be by commercially available or extracted from the red sage root according to this area general extraction methods and obtain.
During liver fibrosis formation and development, the activation of HSCs and propagation are that liver fibrosis is formed and sent out
The key of exhibition.In vitro study shows that salvianolic acid B salt can substantially suppress the propagation of HSCs, can reduce people's conversion
Grouth factor beta1The total amount of secretion, can reduce active form transforming growth factor-beta again1Content, and can suppress to some extent
The expression of Smad albumen, suppresses Smad albumen phosphorylation in the cell and nuclear translocation, so that antagonism transforming growth factor-beta1,
Promote Hepatic Stellate Cell Activation.Experiment in vivo proves that salvianolic acid B salt has obvious effect of anti hepatic fibrosis, and people in hepatic tissue
Transforming growth factor β1, T β R I, the expression of T β RII significantly reduce.
Ganoderic acid A is a kind of triterpene substance, is the main compound in ganoderma lucidum, English name Ganoderic Acid A,
Chemical formula is C30H42O7, can be by commercially available or extracted from ganoderma lucidum according to this area general extraction methods and obtain.Ganoderma lucidum
Sour A can strengthen liver function, strengthen its detoxication, promote the regeneration of hepatitis mice liver, reduce the synthesis of triglycerides；To mouse
The exclusion of acute hepatopathy has facilitation.Ganoderic acid A can improve hepatosis in immunity hepar damnification, reduce liver
Dirty Free Radical Level, anti-lipid peroxidation effect, complete, the normal function of protection liver cell of protection cell biological film.
Rheum emodin has inhibitory action to hepatitis B, to a certain extent with effect of killing the virus.Rheum emodin can be reduced
CCl4 and the hepatic lesion of D-galactosamine induction, play Hepatocyte protection.In stellate cells, rheum emodin is respectively by suppressing
AP-1 signal paths and extracellular signal-regulated kinase activate effectively to suppress PMA and transforming growth factor-beta1Stimulate
TIMP-1 is expressed, so as to playing a part of anti-hepatic fibrosis, promoting liver regeneration and improving liver function.
Preferably, in the active component, Quercetin:RV:Tanshin polyphenolic acid B:The weight ratio of ganoderic acid A is 5-30:
10-40:40-200:1-6。
Or, by weight, the active component of described pharmaceutical composition includes following component：
Quercetin 5-30 parts, RV 10-40, tanshin polyphenolic acid B 40-200 parts, 1-6 parts of ganoderic acid A；Preferably quercitrin
Plain 10-20 parts, RV 15-30 parts, tanshin polyphenolic acid B 60-120 parts, 2-4 parts of ganoderic acid A；More preferably 15 parts of Quercetin, white
20 parts of Li Lu alcohol, 90 parts of tanshin polyphenolic acid B, 3 parts of ganoderic acid A.
Composition can give play to relatively significantly synergistic function in the range of above-mentioned amount ratio.
Preferably, rheum emodin is also included in active component of the present invention.
When rheum emodin is contained in the active component, preferred Quercetin:RV:Tanshin polyphenolic acid B:Ganoderic acid A:Rheum officinale
The weight ratio of element is 5-30:10-40:40-200:1-6:60-200.
Or, by weight, its active component includes following component：Quercetin 5-30 parts, RV 10-40 parts, pellet
Phenolic acid B 40-200 parts, 1-6 parts, rheum emodin 60-200 parts of ganoderic acid A；Preferably Quercetin 10-20 parts, RV 15-30
Part, tanshin polyphenolic acid B 60-120 parts, 2-4 parts, rheum emodin 80-150 parts of ganoderic acid A.More preferably 15 parts of Quercetin, RV
20 parts, 90 parts of tanshin polyphenolic acid B, 3 parts of ganoderic acid A, 100 parts of rheum emodin.
The present invention by the active component further add rheum emodin, can in the mechanism of action from Mutiple Targets,
Multi-angle, multi-level angle have given play to synergistic function, hence it is evident that improve AST or ALT activity.
Pharmaceutical composition of the present invention, can only be made up of (such as commercially available each active raw materials active component
After prepare), or further include that pharmaceutically acceptable auxiliary material is prepared into pharmaceutical preparation.
Wherein, pharmaceutically acceptable auxiliary material is included but is not limited to：Filler, disintegrant, lubricant, suspending agent, bonding
Agent, sweetener, flavouring etc..
Wherein, filler is included but is not limited to：Starch, pregelatinized starch, lactose, mannitol, chitin, microcrystalline cellulose
Element, sucrose etc.；
Disintegrant is included but is not limited to：Starch, pregelatinized starch, microcrystalline cellulose, sodium carboxymethyl starch, crosslinked polyethylene
Pyrrolidones, low-substituted hydroxypropyl cellulose, Ac-Di-Sol etc.；
Lubricant is included but is not limited to：Magnesium stearate, lauryl sodium sulfate, talcum powder, silica etc.；
Suspending agent is included but is not limited to：Polyvinylpyrrolidone, microcrystalline cellulose, sucrose, agar, hydroxypropyl methyl fiber
Element etc.；
Adhesive is included but is not limited to：Starch slurry, polyvinylpyrrolidone, hydroxypropyl methyl cellulose etc.；
Sweetener is included but is not limited to：Saccharin sodium, sucrose, honey element, Aspartame etc.；
Flavouring is included but is not limited to：Sweetener and various essence etc..
Preferably, described pharmaceutical composition is tablet, pill, powder, granule, mixture, syrup, capsule or dripping pill
Agent, preferably tablet.
The preparation of aforementioned pharmaceutical compositions (each formulation) can use ordinary skill in the art means, the present invention not to make this
It is particularly limited to, those skilled in the art can select suitable auxiliary material and preparation method to realize the present invention according to actual conditions.
Invention also provides application of the above-mentioned composition in treatment oxyhepatitis and chronic hepatitis medicine is prepared.
When pharmaceutical composition of the present invention is used to treat oxyhepatitis and chronic hepatitis, each composition can be effectively reduced
Dosage is used alone, significantly mitigates toxic and side effect, with synergistic function.
Specific embodiment
Following examples are used to illustrate the present invention, but are not limited to the scope of the present invention.
Bulk drug is Quercetin, RV, tanshin polyphenolic acid B, ganoderic acid A, rheum emodin, can commercially be bought, and also may be used
It is prepared with by prior art, then is obtained by high performance liquid chromatography control detection level.
In following examples, described " part " can be the unit of weight well known in the art such as μ g, mg, g, kg, or
Its multiple, such as 1/10,1/100,10 times, 100 times.
Embodiment 1 (abbreviation A1)
A kind of pharmaceutical composition is present embodiments provided, its prescription is as follows：
60 parts of 5 parts of Quercetin, 40 parts of RV, 200 parts of tanshin polyphenolic acid B, 1 part of ganoderic acid A and rheum emodin.
Embodiment 2 (abbreviation A2)
A kind of pharmaceutical composition is present embodiments provided, its prescription is as follows：
200 parts of 30 parts of Quercetin, 10 parts of RV, 40 parts of tanshin polyphenolic acid B, 6 parts of ganoderic acid A and rheum emodin.
Embodiment 3 (abbreviation A3)
A kind of pharmaceutical composition is present embodiments provided, its prescription is as follows：
80 parts of 10 parts of Quercetin, 15 parts of RV, 120 parts of tanshin polyphenolic acid B, 2 parts of ganoderic acid A and rheum emodin.
Embodiment 4 (abbreviation A4)
A kind of pharmaceutical composition is present embodiments provided, its prescription is as follows：
150 parts of 20 parts of Quercetin, 30 parts of RV, 60 parts of tanshin polyphenolic acid B, 4 parts of ganoderic acid A and rheum emodin.
Embodiment 5 (abbreviation A5)
A kind of pharmaceutical composition is present embodiments provided, its prescription is as follows：
100 parts of 15 parts of Quercetin, 20 parts of RV, 90 parts of tanshin polyphenolic acid B, 3 parts of ganoderic acid A and rheum emodin.
Embodiment 6 (abbreviation B1)
A kind of pharmaceutical composition is present embodiments provided, its prescription is as follows：
5 parts of Quercetin, 40 parts of RV, 200 parts and ganoderic acid A 1 part of tanshin polyphenolic acid B.
Embodiment 7 (abbreviation B2)
A kind of pharmaceutical composition is present embodiments provided, its prescription is as follows：
30 parts of Quercetin, 10 parts of RV, 40 parts and ganoderic acid A 6 parts of tanshin polyphenolic acid B.
Embodiment 8 (abbreviation B3)
A kind of pharmaceutical composition is present embodiments provided, its prescription is as follows：
10 parts of Quercetin, 15 parts of RV, 120 parts and ganoderic acid A 2 parts of tanshin polyphenolic acid B.
Embodiment 9 (abbreviation B4)
A kind of pharmaceutical composition is present embodiments provided, its prescription is as follows：
20 parts of Quercetin, 30 parts of RV, 60 parts and ganoderic acid A 4 parts of tanshin polyphenolic acid B.
Embodiment 10 (abbreviation B5)
A kind of pharmaceutical composition is present embodiments provided, its prescription is as follows：
15 parts of Quercetin, 20 parts of RV, 90 parts and ganoderic acid A 3 parts of tanshin polyphenolic acid B.
Embodiment 11
The preparation method of embodiment 1-10 any one described pharmaceutical compositions is present embodiments provided, specifically, weighing each
Raw material, mixing is obtained final product.
Embodiment 12
A kind of tablet using embodiment any one of 1-10 described pharmaceutical composition as active component is present embodiments provided,
The tablet with starch, microcrystalline cellulose, hydroxypropyl cellulose, low-substituted hydroxypropyl cellulose and magnesium stearate as auxiliary material, according to
This area conventional technology is prepared.
Embodiment 13
Present embodiments provide a kind of capsule using embodiment any one of 1-10 described pharmaceutical composition as active component
Agent, the capsule is prepared with starch, mannitol and microcrystalline cellulose as auxiliary material according to this area conventional technical means.
Comparative example 1
Compared with Example 1, distinctive points are only that, the resveratrol in active component is replaced with 120 parts of Sebivos.
Comparative example 2
Compared with Example 1, distinctive points are only that, the ganoderic acid A in active component is replaced with 120 parts of Sebivos.
Comparative example 3
Compared with Example 1, distinctive points are only that, the tanshin polyphenolic acid B in active component is replaced with 120 parts of Sebivos.
Experimental example 1
CCl4Chronic liver injury animal model is to cause one of classical model of hepatic injury, is widely used for hepatitis medicament
Research and development.
To CCl4Cause the influence (x ± S) of mouse liver injury model
The male ICR mouse that body weight is 22-24g is taken, 16 groups, Normal group, solvent (0.5% carboxymethyl are randomly divided into
Sodium cellulosate) control group, model group and administration group (contrast groups 1, contrast groups 2, contrast groups 3, A1, A2, A3, A4, A5, B1, B2,
B3, B4, B5), every group 10, to administration group gastric infusion, twice daily, 50mg/kg body weight is every time, solvent control group is given
The sodium carboxymethylcellulose of equivalent 0.5%, Normal group is given to give normal saline replacement, continuous 7 days respectively with model group.
After last dose after 3 hours in addition to Normal group, the equal intraperitoneal injection 0.5%CCl of remaining each group animal4Soybean oil solution 10mL/
Kg body weight, takes blood and surveys Serum ALT after 17h by eyeball rear vein beard, and liver is taken while pulling cervical vertebra and putting to death mouse, prepares liver even
Slurry, takes supernatant and surveys liver TG, and take hepatic tissue and be fixed in 10% methanol solution, makees check pathological section.The results are shown in Table.
Table 1：Different components ratio is to CCl4Cause the influence of mouse liver injury model
From table：A, B composition series and contrast groups can significantly reduce elevated Serum ALT and liver TG, with
Model group relatively has significant difference, but A composition series are substantially better than B composition series, better than contrast groups.
The treatment of the hepatitis B of experimental example 2
50 treatment targets of selection, by September, 2000《Virus hepatitis control prece》Standard diagnostics.Wherein male 25
Example, women 25, age 18-60 Sui.
For 50 patients, the tablet prepared in embodiment 5 is taken.1 day 3 times, 4 tablets once.Treatment 90 days.
Criterion of therapeutical effect
It is effective：After treatment, seralbumin, globulin, gamma globulin, A/G, Serum ALT are normal.
Effectively：After treatment, These parameters have 1 improver, i.e.,：1. albumin rise 5g/L and more than；2. globulin
Decline at least 3g/L；3. gamma globulin declines at least 1.5g/L；4. A/G rises at least 0.5%.
It is invalid：Without above-mentioned changer after treatment.
It is as a result as follows for above-mentioned 50 patients：Wherein effective 39 people, effective 11 people, invalid 0 people, efficient 100%.
Although the present invention is described in detail above to have used general explanation and specific embodiment, at this
On the basis of invention, it can be made some modifications or improvements, this will be apparent to those skilled in the art.Therefore,
These modifications or improvements, belong to the scope of protection of present invention without departing from theon the basis of the spirit of the present invention.
Claims (10)
1. a kind of pharmaceutical composition, it is characterised in that its active component includes Quercetin, RV, tanshin polyphenolic acid B and ganoderic acid
A。
2. pharmaceutical composition according to claim 1, it is characterised in that in the active component, Quercetin:Bai Lilu
Alcohol:Tanshin polyphenolic acid B:The weight ratio of ganoderic acid A is 5-30:10-40:40-200:1-6.
3. pharmaceutical composition according to claim 1 and 2, it is characterised in that by weight, its active component is included such as
Lower component：Quercetin 5-30 parts, RV 10-40 parts, tanshin polyphenolic acid B 40-200 parts, 1-6 parts of ganoderic acid A；Preferably quercitrin
Plain 10-20 parts, RV 15-30 parts, tanshin polyphenolic acid B 60-120 parts, 2-4 parts of ganoderic acid A.
4. the composition according to claim any one of 1-3, it is characterised in that also include rheum officinale in the active component
Element.
5. pharmaceutical composition according to claim 4, it is characterised in that in the active component, Quercetin:Bai Lilu
Alcohol:Tanshin polyphenolic acid B:Ganoderic acid A:The weight ratio of rheum emodin is 5-30:10-40:40-200:1-6:60-200.
6. the pharmaceutical composition according to claim 4 or 5, it is characterised in that by weight, its active component is included such as
Lower component：Quercetin 5-30 parts, RV 10-40 parts, tanshin polyphenolic acid B 40-200 parts, 1-6 parts of ganoderic acid A, rheum emodin 60-
200 parts；Preferably Quercetin 10-20 parts, RV 15-30 parts, tanshin polyphenolic acid B 60-120 parts, 2-4 parts of ganoderic acid A, rheum officinale
It is plain 80-150 parts.
7. the pharmaceutical composition according to claim any one of 1-6, it is characterised in that in described pharmaceutical composition further
Including pharmaceutically acceptable auxiliary material.
8. pharmaceutical composition according to claim 7, it is characterised in that the composition be tablet, pill, powder,
Granula, mixture, syrup, capsule or pill.
9. pharmaceutical composition according to claim 8, it is characterised in that the composition is tablet.
10. the pharmaceutical composition described in any one of claim 1-9 is in treatment oxyhepatitis and chronic hepatitis medicine is prepared
Using.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611238398.8A CN106822152B (en) | 2016-12-28 | 2016-12-28 | Pharmaceutical composition and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611238398.8A CN106822152B (en) | 2016-12-28 | 2016-12-28 | Pharmaceutical composition and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106822152A true CN106822152A (en) | 2017-06-13 |
| CN106822152B CN106822152B (en) | 2019-12-13 |
Family
ID=59114463
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611238398.8A Active CN106822152B (en) | 2016-12-28 | 2016-12-28 | Pharmaceutical composition and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106822152B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117064899A (en) * | 2023-10-13 | 2023-11-17 | 暨南大学附属第一医院（广州华侨医院） | Application of ganoderic acid A in preparation of medicine for treating castration resistant prostate cancer |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1679891A (en) * | 2005-01-14 | 2005-10-12 | 郭来旺 | Method for producing capsules of Huganning for liver |
| CN1857435A (en) * | 2006-03-30 | 2006-11-08 | 贵州益佰制药股份有限公司 | Quality control method for Huganning preparation |
| CN1969963A (en) * | 2006-09-25 | 2007-05-30 | 贵州信邦制药股份有限公司 | Method for extracting medicament effective component for treating hepatitis and medicinal composition thereof |
| CN101156839A (en) * | 2007-07-25 | 2008-04-09 | 北京星昊医药股份有限公司 | White hellebore alcohol and red phenolic acid B compound recipe preparation and its application |
| CN102451175A (en) * | 2010-11-01 | 2012-05-16 | 中国科学院大连化学物理研究所 | Resveratrol and bioflavonoid composition as well as preparation and application thereof |
| JP2014185170A (en) * | 2014-06-18 | 2014-10-02 | Apion Japan Kk | Sirtuin 1 (sirt1) gene activator, and telomerase reverse transcriptase (tert) gene activator |
| US20140302178A1 (en) * | 2013-04-04 | 2014-10-09 | Hanan Polansky | Natural Product for Decreasing Symptoms During Viral Infections |
| CN106018629A (en) * | 2016-08-09 | 2016-10-12 | 云南海沣药业有限公司 | Bushy knotweed leaf fingerprint HPLC method and its use in bushy knotweed leaf capsule quality control |
-
2016
- 2016-12-28 CN CN201611238398.8A patent/CN106822152B/en active Active
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1679891A (en) * | 2005-01-14 | 2005-10-12 | 郭来旺 | Method for producing capsules of Huganning for liver |
| CN1857435A (en) * | 2006-03-30 | 2006-11-08 | 贵州益佰制药股份有限公司 | Quality control method for Huganning preparation |
| CN1969963A (en) * | 2006-09-25 | 2007-05-30 | 贵州信邦制药股份有限公司 | Method for extracting medicament effective component for treating hepatitis and medicinal composition thereof |
| CN101156839A (en) * | 2007-07-25 | 2008-04-09 | 北京星昊医药股份有限公司 | White hellebore alcohol and red phenolic acid B compound recipe preparation and its application |
| CN102451175A (en) * | 2010-11-01 | 2012-05-16 | 中国科学院大连化学物理研究所 | Resveratrol and bioflavonoid composition as well as preparation and application thereof |
| US20140302178A1 (en) * | 2013-04-04 | 2014-10-09 | Hanan Polansky | Natural Product for Decreasing Symptoms During Viral Infections |
| JP2014185170A (en) * | 2014-06-18 | 2014-10-02 | Apion Japan Kk | Sirtuin 1 (sirt1) gene activator, and telomerase reverse transcriptase (tert) gene activator |
| CN106018629A (en) * | 2016-08-09 | 2016-10-12 | 云南海沣药业有限公司 | Bushy knotweed leaf fingerprint HPLC method and its use in bushy knotweed leaf capsule quality control |
Non-Patent Citations (4)
| Title |
|---|
| K.-C. CHOI等: "Inhibitory effects of quercetin on aflatoxin B 1 -induced hepatic damage in mice", 《FOOD AND CHEMICAL TOXICOLOGY 》 * |
| NOEMÍ ARIAS等: "Liver delipidating effect of a combination of resveratrol and quercetin in rats fed an obesogenic diet", 《JOURNAL OF PHYSIOLOGY AND BIOCHEMISTRY 》 * |
| 朱方石等: "护肝宁对CCl4诱导肝细胞损伤保护作用的研究", 《辽宁中医杂志 》 * |
| 黄丽华等: "HPLC测定护肝宁片中的大黄素", 《光谱实验室》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117064899A (en) * | 2023-10-13 | 2023-11-17 | 暨南大学附属第一医院（广州华侨医院） | Application of ganoderic acid A in preparation of medicine for treating castration resistant prostate cancer |
| CN117064899B (en) * | 2023-10-13 | 2024-01-23 | 暨南大学附属第一医院（广州华侨医院） | Application of ganoderic acid A in preparation of medicine for treating castration resistant prostate cancer |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106822152B (en) | 2019-12-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI678211B (en) | Uses of cistanche tubulosa extract and isoacteoside in protecting muscles | |
| CN105997985A (en) | Application of marihuana extract in preparation of gout treating medicine | |
| CN101214288A (en) | Traditional Chinese medicinal composition for treating hepatitis and its preparation | |
| CN101099753A (en) | Preparation method and application for general saponin of cortex ilecis rotundae | |
| CN103463409B (en) | Traditional Chinese medicine formula for treating heart qi deficiency | |
| CN106236815A (en) | Resina garciniae extract application in preventing and treating diabetes | |
| CN106822152A (en) | A kind of pharmaceutical composition and its application | |
| CN102772611A (en) | Traditional Chinese medicine composition and preparation method and application thereof | |
| CN109350632A (en) | A kind of Chinese medicine composition for antipyretic-antalgic | |
| CN101011457A (en) | Traditional Chinese medicine composition with immunological enhancement function | |
| KR20140108104A (en) | Compositions comprising the combined extract of Artemisia iwayomogi and Curcuma longa for treating, inhibiting or preventing obesity-related disease | |
| CN103735630B (en) | A kind of Chinese medicine for the treatment of gout | |
| CN103735830B (en) | One is treated osteoporotic Chinese medicine composition | |
| CN102204956B (en) | Chinese medicinal composition used at stroke recovery period and preparation method thereof | |
| CN104510857B (en) | A kind of Chinese medicinal effective-part composition for blood fat reducing and preparation thereof | |
| CN101607009B (en) | Pharmaceutical composition for treating cold | |
| CN104127545B (en) | New application of murraya tetramera huang and extract thereof in preparation of medicines | |
| CN103505488A (en) | Traditional Chinese medicine composition of pseudo-ginseng and sea-buckthorn and preparation method of composition | |
| CN103768454A (en) | Composition for preventing and treating HIV/AIDS (Human Immunodeficiency Virus/ Acquired Immune Deficiency Syndrome) and preparation method thereof | |
| CN101991678B (en) | Application of India madder root in preparing medicine for preventing and treating kidney disease | |
| CN101537150B (en) | Medicine for treating pulmonary tuberculosis | |
| CN106138031A (en) | MoracinC is used for the application treating in the medicine of diabetes in preparation | |
| CN101417075A (en) | Traditional Chinese medicine for treating respiratory system disease | |
| CN104666328A (en) | Application of traditional Chinese medicine polysaccharide in medicine and extraction method of traditional Chinese medicine polysaccharide | |
| CN104188992B (en) | A kind of pharmaceutical composition for treating nephrotic syndrome |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |